Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 12
Submit an article Journal homepage
460
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Ohad BenjaminiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Hagop KantarjianDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Mary Beth RiosDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Elias JabbourDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Susan O’BrienDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Preetesh JainDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Marylou Cardenas-TuranzasDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Stefan FaderlDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Farhad RavandiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Gautam BorthakurDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Alfonso Quintas-CardamaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
&
Jorge CortesDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
 show all
Pages 2879-2886 | Received 11 Jul 2013, Accepted 29 Jul 2013, Published online: 10 Sep 2013

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Matteo Dragani, Giovanna Rege-Cambrin, Dario Ferrero, Elisabetta Abruzzese, Patrizia Pregno, Chiara Elena, Michele Cedrone, Marco Santoro, Giacomo Andreani, Giuseppe Saglio & Carmen Fava. (2019) Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. Leukemia & Lymphoma 60:13, pages 3330-3332.
Read now
Masaki Iino, Takeo Yamamoto & Yuma Sakamoto. (2019) Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution. Hematology 24:1, pages 355-361.
Read now

Articles from other publishers (23)

Nuno Cerveira, Susana Bizarro, Manuel R. Teixeira & José M. Mariz. (2021) When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently. Current Treatment Options in Oncology 22:6.
Crossref
Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko & A.G. Turkina. (2021) Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial. Clinical oncohematology 14:1, pages 1-12.
Crossref
Elisa Diral, Silvia MoriLaura AntoliniElisabetta Abruzzese, Philipp Le CoutreBruno MartinoEster PungolinoChiara ElenaMicaela BergamaschiSarit AssoulineEros Di BonaAntonella GozziniMarcio Andrade-Campos, Fabio StagnoAlessandra Iurlo, Alessandra PirolaDiletta Fontana, Jessica Petiti, Maria Luisa Bonanomi, Patrizia Crivori, Rocco Piazza, Carmen Fava & Carlo Gambacorti-Passerini. (2020) Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood 136:19, pages 2237-2240.
Crossref
David M. Ross & Timothy P. Hughes. (2020) Treatment-free remission in patients with chronic myeloid leukaemia. Nature Reviews Clinical Oncology 17:8, pages 493-503.
Crossref
Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour & Jorge Cortes. (2019) Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology & Oncology 12:1.
Crossref
Richard E. Clark. (2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. Current Hematologic Malignancy Reports 14:6, pages 507-514.
Crossref
Zhanet Grudeva-Popova, Emil Spasov, Vasko Graklanov, Katya Sotirova, Veselin Popov, Gueorgui Balatzenko & Ivanka Hristova. (2019) Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?. EMJ Hematology, pages 80-84.
Crossref
Richard E Clark, Fotios Polydoros, Jane F Apperley, Dragana Milojkovic, Katherine Rothwell, Christopher Pocock, Jennifer Byrne, Hugues de Lavallade, Wendy Osborne, Lisa Robinson, Stephen G O'Brien, Lucy Read, Letizia Foroni & Mhairi Copland. (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology 6:7, pages e375-e383.
Crossref
Jorge E. Cortes. (2018) A second-generation TKI should always be used as initial therapy for CML. Blood Advances 2:24, pages 3653-3655.
Crossref
Juan Carlos Hernández-Boluda, Arturo Pereira, Irene Pastor-Galán, Alberto Alvarez-Larrán, Alisa Savchuk, José Manuel Puerta, José María Sánchez-Pina, Rosa Collado, Alvaro Díaz-González, Anna Angona, Miguel Sagüés, Valentín García-Gutiérrez, Concepción Boqué, Santiago Osorio, Rolando Vallansot, Luis Palomera, Arantxa Mendizábal, Luis Felipe Casado, Manuel Pérez-Encinas, Raúl Pérez-López, Francisca Ferrer-Marín, Fermín Sánchez-Guijo, Carmen García, Natalia de las Heras, José Luis López-Lorenzo, Francisco Cervantes & Juan Luis Steegmann. (2018) Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer Journal 8:10.
Crossref
Jorge Cortes, Delphine Rea & Jeffrey H. Lipton. (2018) Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors. American Journal of Hematology.
Crossref
Delphine Rea & Jean-Michel Cayuela. (2017) Treatment-free remission in patients with chronic myeloid leukemia. International Journal of Hematology 108:4, pages 355-364.
Crossref
Pierre Laneuville. (2018) When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Current Treatment Options in Oncology 19:3.
Crossref
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Zhengjia Chen, Amelia A. Langston, Brittany Hill, Martha Arellano, Fuad El-Rassi, Audrey Kim, Anand Jillella, Vamsi K. Kota, Imre Bod? & Hanna Jean Khoury. (2017) Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?. Cancer 123:13, pages 2482-2488.
Crossref
Leonardo Campiotti, Matteo Basilio Suter, Luigina Guasti, Rocco Piazza, Carlo Gambacorti-Passerini, Anna Maria Grandi & Alessandro Squizzato. (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A?systematic review and a meta-analysis. European Journal of Cancer 77, pages 48-56.
Crossref
Delphine ReaFranck E. NicoliniMichel TulliezFrançois GuilhotJoelle GuilhotAgnès Guerci-BreslerMartine GardembasValérie CoiteuxGaelle GuillermLaurence LegrosGabriel EtienneJean-Michel PignonBruno VillemagneMartine Escoffre-BarbeJean-Christophe IanottoAude CharbonnierHyacinthe Johnson-Ansah, Marie-Pierre NoelPhilippe Rousselot & François-Xavier Mahon. (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:7, pages 846-854.
Crossref
Jorge E. Cortes & Andreas Hochhaus. (2017) Reply to K.R. Hoffman. Journal of Clinical Oncology 35:5, pages 567-568.
Crossref
A. G. Turkina, E. Yu. Chelysheva, V. A. Shuvaev, G. A. Gusarova, A. V. Bykova, O. A. Shukhov, A. N. Petrova, M. V. Vakhrusheva, S. R. Goryacheva, L. Yu. Kolosova, P. S. Krasikova, M. S. Fominykh, I. S. Martynkevich, A. O. Abdullaev, A. B. Sudarikov & V. G. Savchenko. (2017) Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy. Terapevticheskii arkhiv 89:12, pages 86.
Crossref
Sheena Bhalla, Douglas Tremblay & John Mascarenhas. (2016) Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions. Clinical Lymphoma Myeloma and Leukemia 16:9, pages 488-494.
Crossref
Timothy P. Hughes & David M. Ross. (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:1, pages 17-23.
Crossref
Philip A. Thompson, Hagop M. Kantarjian & Jorge E. Cortes. (2015) Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clinic Proceedings 90:10, pages 1440-1454.
Crossref
Giovanni Caocci, Marianna Greco & Giorgio La Nasa. (2014) Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report. Journal of Medical Case Reports 8:1.
Crossref
David M. Ross & Timothy P. Hughes. (2014) How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. British Journal of Haematology 166:1, pages 3-11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.